DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/500642/south_korea_pharma) has announced the addition of the "South Korea Pharmaceuticals and Healthcare Report Q4 2011" report to their offering.
Business Monitor International's South Korea Pharmaceuticals and Healthcare Report provides industry professionals and strategists, corporate analysts, pharmaceutical associations, government departments and regulatory bodies with independent forecasts and competitive intelligence on South Korea's pharmaceuticals and healthcare industry.
BMI View: Unlike some observers, BMI classes South Korea as a developed country and this is underpinned by the balanced risk/reward profile of its pharmaceutical market. Negative attributes include the sub-standard enforcement of intellectual property rights, market access issues and price cuts. Demand for pharmaceuticals will be supported by an ageing population and a culture of medication. The anticipated free trade agreement with the US will be emphatically welcomed by foreign multinational drugmakers.
Headline Expenditure Projections
- Pharmaceuticals: KRW13,212bn (US$11.43bn) in 2010 to KRW13,917bn (US$12.65bn) in 2011; +5.3% in local currency terms and +10.7% in US dollar terms. Our forecast has been revised down from Q311 due to macroeconomic factors.
- Healthcare: KRW78,406bn (US$67.80bn) in 2010 to KRW83,873bn (US$76.25bn) in 2011; +7.0% in local currency terms and 12.5% in US dollar terms. BMIs forecast has been revised down moderately from Q311 due to macroeconomic factors.
- Medical devices: KRW4,151bn (US$3.59bn) in 2010 to KRW4,512bn (US$4.10bn) in 2011; +8.7% in local currency terms and 14.3% in US dollar terms.
Our forecast has been revised down slightly from Q311 due to macroeconomic factors.
Companies Mentioned:
- Dong-A
- Chong Kun Dang Pharmaceutical
- Hanmi Pharmaceutical Co
- Yuhan Corporation
- Daewoong Pharmaceutical
- Bukwang Pharmaceutical Company
- Kuhnil Pharmaceutical
- Choongwae
For more information visit http://www.researchandmarkets.com/research/500642/south_korea_pharma